Advisory Council for the Elimination of Tuberculosis Meeting (ACET), 70629-70630 [2020-24505]

Agencies

• Centers for Disease Control and Prevention
• DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 85, Number 215 (Thursday, November 5, 2020)]
[Notices]
[Pages 70629-70630]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-24505]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC-2020-0116]


Advisory Council for the Elimination of Tuberculosis Meeting 
(ACET)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of meeting and request for comment.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Federal Advisory Committee Act, the 
Centers for Disease Control and Prevention (CDC), announces the 
following meeting of Advisory Council for the Elimination of 
Tuberculosis (ACET). This meeting is open to the public, limited only 
by audio and web conference lines (1,000 audio and web conference lines 
are available). The public may join by accessing the meeting 
information below. Time will be available for oral public comment.

DATES: The meeting will be held on December 8, 2020 from 10:00 a.m. to 
4:00 p.m., EST, and December 9, 2020 from 10:00 a.m. to 12:00 p.m., 
EST.
    Written comments must be received on or before December 6, 2020, 
EST.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2020-
0116 by either of the following methods. CDC does not accept comment by 
email.
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments.
     Mail: Staci Morris, CDC, 1600 Clifton Road NE, Mailstop 
US8-6, Atlanta, Georgia 30329-4027, Attn: ACET Meeting.
    Instructions: All submissions received must include the Agency name 
and Docket Number. All relevant comments received in conformance with 
the https://www.regulations.gov suitability policy will be posted 
without change to https://www.regulations.gov, including any personal 
information provided. For access to the docket to read background 
documents or comments received, go to https://www.regulations.gov. 
Written public comments submitted by December 6, 2020, EST will be 
included in the official record of the meeting.
    Meeting information: The teleconference access is noted as follows. 
Please note the access information is different for each meeting date.

December 8, 2020, 10:00 a.m.-4:00 p.m., EST (US and Canada)

    Please click the link below to join the webinar: https://cdc.zoomgov.com/j/1610532751?pwd=TUlQRElrdXI5QVMzdjJGSzN6eXluUT09.
    Passcode: A6d&BRMn.
    Or iPhone one-tap: US: +16692545252,,1610532751#,,,,,,0#,,38868739# 
or +16468287666,,1610532751#,,,,,,0#,,38868739#.
    Or Telephone: Dial (for higher quality, dial a number based on your 
current location): US: +1 669 254 5252 or +1 646 828 7666.
    Webinar ID: 161 053 2751.
    Passcode: 38868739.
    International numbers available: https://cdc.zoomgov.com/u/abU0Q7Xcvi.
    Or an H.323/SIP room system: H.323: 161.199.138.10 (US West) or 
161.199.136.10 (US East).
    Meeting ID: 161 053 2751.
    Passcode: 38868739.
    SIP: [email protected].
    Passcode: 38868739.

December 9, 2020, 10:00 a.m.-12:00 p.m., EST (US and Canada)

    Please click the link below to join the webinar: https://cdc.zoomgov.com/j/1601429901?pwd=M1dtb1dtVkFYUitrYXFvM0hodk1mUT09.
    Passcode: 8TS16+u$.
    Or iPhone one-tap: US: +16692545252,,1601429901#,,,,,,0#,,46612157 
or +16468287666,,1601429901#,,,,,,0#,,46612157#.
    Or Telephone: Dial (for higher quality, dial a number based on your 
current location): US: +1 669 254 5252 or +1 646 828 7666.
    Webinar ID: 160 142 9901.
    Passcode: 46612157.
    International numbers available: https://cdc.zoomgov.com/u/abqzxBE5mL.
    Or an H.323/SIP room system: H.323: 161.199.138.10 (US West) or 
161.199.136.10 (US East).
    Meeting ID: 160 142 9901.
    Passcode: 46612157.
    SIP: [email protected].
    Passcode: 46612157.

FOR FURTHER INFORMATION CONTACT: Staci Morris, Committee Management 
Specialist, CDC, 1600 Clifton Road, NE, Mailstop US8-6, Atlanta, 
Georgia 30329-4027; Telephone: 404-718-7479; Email: [email protected].

SUPPLEMENTARY INFORMATION:
    Purpose: This Council advises and makes recommendations to the 
Secretary of Health and Human Services, the Assistant Secretary for 
Health, and the Director, CDC, regarding the elimination of 
tuberculosis (TB). Specifically, the Council makes recommendations 
regarding policies, strategies, objectives, and priorities; addresses 
the development and application of new technologies; and reviews the 
extent to which progress has been made toward eliminating tuberculosis.

Public Participation

    Interested persons or organizations are invited to participate by 
submitting written views, recommendations, and data. Comments received, 
including attachments and other supporting materials, are part of the 
public record and are subject to public disclosure. Comments will be 
posted on https://www.regulations.gov. Therefore, do not include any 
information in your comment or supporting materials that you consider 
confidential or inappropriate for public disclosure. If you include 
your name, contact information, or other information that identifies 
you in the body of your comments, that information will be on public 
display. CDC will review all submissions and may choose to redact, or 
withhold, submissions containing private or proprietary information 
such as Social Security numbers, medical information, inappropriate 
language, or duplicate/near duplicate examples of a mass-mail campaign. 
CDC will carefully consider all comments submitted into the docket. CDC 
does not accept comment by email.
    Procedure for Public Comment: Time will be available for public 
comment. Persons who desire to make an oral

[[Page 70630]]

statement, may request it at the time of the public comment period on 
December 9, 2020 at 11:55 a.m., EST.
    Written Public Comment: The public is welcome to submit written 
comments in advance of the meeting. Comments should be submitted in 
writing according to the instructions provided. The deadline for 
receipt of written public comment is December 6, 2020, EST. All 
requests must contain the name, address, and organizational affiliation 
of the speaker, as well as the topic being addressed. Written comments 
received in advance of the meeting will be included in the official 
record of the meeting.
    Matters to be Considered: The agenda will include discussions and 
updates on: (1) TBTC Study 31: Rifapentine-containing Tuberculosis 
Treatment Shortening Regimens; (2) Latent Tuberculosis Infection (LTBI) 
Community Engagement; (3) Bedaquiline + Pretomanid + Linezolid (BPal) 
Clinical Guidance; (4) Nitrosamine Impurities in Rifamycins; and (5) 
Electronic Directly Observed Therapy (eDOT). Agenda items are subject 
to change as priorities dictate.
    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-24505 Filed 11-4-20; 8:45 am]
BILLING CODE 4163-18-P